Key Takeaways
- • Function Health secured $450 million in non-dilutive growth financing from General Catalyst's Customer Value Fund, one of the fund's largest investments to date, structured to tie capital to customer growth rather than equity dilution.
- • The Austin-based preventive health platform has scaled to 500,000+ members and completed over 100 million lab tests since launching its beta in 2023, offering 160+ biomarker tests plus advanced imaging (full-body MRI and CT scans) for $365 annual membership.
- • Function's bundled prevention model targets a massive market gap: over 100 million Americans lack primary care access, average appointment wait times reach 31 days, and 90% of the U.S.'s $4.9 trillion annual healthcare spend treats diseases often detectable years before symptom onset.
- • The funding follows Function's strategic acquisitions of Getlabs and SuppCo, expanding its integrated approach to early disease detection across lab testing, imaging, and supplementation services.
- • General Catalyst's CVF investment signals institutional confidence in preventive care economics; the $450 million commitment follows a similar $200 million deployment to healthcare AI platform Commure in June 2025, indicating sustained venture appetite for healthcare infrastructure plays.
Summary
Function Health has closed $450 million in growth financing from General Catalyst's Customer Value Fund, a non-dilutive capital structure that ties funding deployment to customer acquisition metrics rather than traditional equity dilution. The deal represents one of CVF's largest commitments to date and underscores institutional venture capital's expanding thesis around preventive healthcare infrastructure.
The Austin-based platform, founded in 2021 by Jonathan Swerdlin, Pranitha Patil, Dr. Mark Hyman, Seth Weisfeld, Mike Nemke, and Dan Swerdlin, has built a membership-based model combining 160+ laboratory biomarkers with advanced imaging capabilities—approximately five times the diagnostic depth of a standard annual physical. The company's $365 annual membership price point positions preventive screening as an accessible primary care alternative. Since launching its beta in 2023, Function has acquired 500,000+ members and processed over 100 million lab tests, demonstrating material traction in a fragmented primary care market.
The investment thesis addresses demonstrable healthcare system dysfunction. Over 100 million Americans currently lack a primary care physician, average appointment wait times have extended to 31 days, and three in four U.S. adults manage at least one chronic condition. Critically, 90% of the nation's $4.9 trillion in annual healthcare expenditure targets treatment of diseases detectable years before symptomatic onset. Function's preventive screening model aims to shift this cost curve by enabling early intervention at lower disease stages.
Function's recent acquisitions of Getlabs (point-of-care lab collection) and SuppCo (supplementation) indicate a strategy to build an integrated preventive health ecosystem, reducing friction across testing, diagnostics, and downstream therapeutic recommendations. General Catalyst's non-dilutive financing vehicle, which prioritizes capital efficiency tied to customer metrics rather than dilutive rounds, suggests the fund expects Function's unit economics and customer acquisition costs to sustain accelerating growth without traditional equity distribution pressures.
The $450 million CVF deployment follows General Catalyst's $200 million commitment to healthcare AI platform Commure in June 2025, signaling sustained institutional appetite for healthcare infrastructure modernization plays positioned at the intersection of data analytics, preventive medicine, and consumer health access.
The Austin-based platform, founded in 2021 by Jonathan Swerdlin, Pranitha Patil, Dr. Mark Hyman, Seth Weisfeld, Mike Nemke, and Dan Swerdlin, has built a membership-based model combining 160+ laboratory biomarkers with advanced imaging capabilities—approximately five times the diagnostic depth of a standard annual physical. The company's $365 annual membership price point positions preventive screening as an accessible primary care alternative. Since launching its beta in 2023, Function has acquired 500,000+ members and processed over 100 million lab tests, demonstrating material traction in a fragmented primary care market.
The investment thesis addresses demonstrable healthcare system dysfunction. Over 100 million Americans currently lack a primary care physician, average appointment wait times have extended to 31 days, and three in four U.S. adults manage at least one chronic condition. Critically, 90% of the nation's $4.9 trillion in annual healthcare expenditure targets treatment of diseases detectable years before symptomatic onset. Function's preventive screening model aims to shift this cost curve by enabling early intervention at lower disease stages.
Function's recent acquisitions of Getlabs (point-of-care lab collection) and SuppCo (supplementation) indicate a strategy to build an integrated preventive health ecosystem, reducing friction across testing, diagnostics, and downstream therapeutic recommendations. General Catalyst's non-dilutive financing vehicle, which prioritizes capital efficiency tied to customer metrics rather than dilutive rounds, suggests the fund expects Function's unit economics and customer acquisition costs to sustain accelerating growth without traditional equity distribution pressures.
The $450 million CVF deployment follows General Catalyst's $200 million commitment to healthcare AI platform Commure in June 2025, signaling sustained institutional appetite for healthcare infrastructure modernization plays positioned at the intersection of data analytics, preventive medicine, and consumer health access.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.